Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of aficamten in symptomatic obstructive hypertrophic cardiomyopathy
MOH_2021-12-21_010445Phase 3Not yet recruiting
- Sponsor
- Cytokinetics
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Aficamten with Placebo (2 arms). Planned start Dec 2021; status: not yet recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on MOH_2021-12-21_010445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-12-21_010445.